-
1 Comment
Linical Co., Ltd is currently in a long term uptrend where the price is trading 24.6% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Linical Co., Ltd's total revenue sank by 9.4% to $3B since the same quarter in the previous year.
Its net income has increased by 1.5% to $171M since the same quarter in the previous year.
Based on the above factors, Linical Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| CurrencyCode | JPY |
| Exchange | TSE |
| ISIN | JP3974530002 |
| Dividend Yield | 3.9% |
|---|---|
| Beta | 0.41 |
| Target Price | 2700 |
| PE Ratio | 19.05 |
| Market Cap | 16B |
Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 2183.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
